Global consortia should prioritize multicenter trials targeting NF-κB, STAT6, and GATA-3, constructing AD-specific molecular subgroups through integrating multi-omics like transcriptomics and skin barrier lipidomics. The gene discussed is NFKB1; the disease is Alzheimer disease.